BMRNBioMarin Pharmaceutical Inc.
Price
+0.81%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, no red flags, price roughly fair, growth steady, the market undecided.
BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Our San Rafael, California-based company, founded in 1997, has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, we seek to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
BioMarin Pharmaceutical Inc. (BMRN) reported revenue of $990M in Q2 2026 (quarter ended Jun 30, 2026), up 20% from the same quarter a year earlier. That came with a gross margin of 80% and net income of $45M (4.5% of revenue). For the full year FY2025, revenue was $3.22B (+13% year on year) and net income $349M. Its largest product in Q2 2026 was VOXZOGO at $253M, 26% of the disclosed total, just ahead of VIMIZIM at 20%. The next results filing is expected around Jan 11, 2027, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 30, 2026On September 24, 2026, BioMarin Pharmaceutical Inc. (BioMarin) entered into a Settlement and License Agreement (the Agreement) with Ascendis Pharma A/S (Ascendis)Material agreement entered · Form 8-K
- Sep 15, 2026On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome.Other event · Form 8-K
- Sep 14, 2026On September 10, 2026, the Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size of the Board from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., to the Board, to be effective September 10, 2026 (the Appointment Date)Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $989.7MThe company’s own SEC segment disclosure.
- VOXZOGO$252.5M26%
- VIMIZIM$194.4M20%
- NAGLAZYME$135.3M14%
- PALYNZIQ$135.2M14%
- GALAFOLD$105.7M11%
- BRINEURA$51.4M5%
- Other (5)$115.3M12%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.